8-K current report · filed Sep 8, 2026

Sana Biotechnology, Inc. (SANA) 8-K Current Report: September 8, 2026

Item EX-99.1Item 7.01SANA overview

Short answer

Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on September 8, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Updated corporate presentation released September 8, 2026 for investor-conference discussions.

Sana Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation released September 8, 2026 for investor-conference discussions
  • Exhibit 99.1 contains the presentation, potentially detailing updated strategy, pipeline, or clinical priorities
  • Investor significance depends on presentation content, particularly any changes to development timelines or program focus

Item EX-99.1 · Exhibit EX-99.1

  • SC451 IND filing and Phase 1/2 initiation targeted for 2026, creating near-term clinical catalysts in type 1 diabetes
  • UP421 demonstrated hypoimmune islet-cell survival and function through 14 months without immunosuppression
  • UP421 met all primary and secondary endpoints with no therapy-related adverse events reported
  • SG293 showed 15–20% circulating CD8+ T-cell transduction in NHPs, complete B-cell depletion, and potential NHL data in 1H 2027
  • SG227 multiple-myeloma clinical study could begin as early as 2027, expanding Sana’s in-vivo CAR-T opportunity beyond diabetes

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Sana Biotechnology, Inc. 8-K filings

Get the next SANA 8-K as it lands

Follow SANA for push alerts, or ask the research agent what this filing means.